Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Ruan, Xiaoyang ^a,b   Kocher, Jean Pierre A ^a   Pommier, Yves ^b   Liu, Hongfang ^a,b   Reinhold, William C ^b  

^a Mayo Clinic   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CHROMOSOME FRAGILE SITE; CONTROLLED STUDY; COPY NUMBER VARIATION; CYTOGENETICS; GENETIC ASSOCIATION; GENOME; HAPLOTYPE MAP; HEMIZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; NATIONAL HEALTH ORGANIZATION; NUCLEOTIDE SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; HOMOZYGOTE; HUMAN GENOME; NEOPLASM; PATHOLOGY; TUMOR CELL LINE; UNITED STATES;

CELL LINE, TUMOR; CHROMOSOME FRAGILE SITES; GENOME, HUMAN; HAPMAP PROJECT; HOMOZYGOTE; HUMANS; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; UNITED STATES;

EID: 84863062015     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031628     Document Type: Article

References (46)

1. Knudson AG, (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68: 820-823.
2. Knudson AG, (2001) Two genetic hits (more or less) to cancer. Nat Rev Cancer 1: 157-162.
3. Shen P, Huang HV, (1986) Homologous recombination in Escherichia coli: dependence on substrate length and homology. Genetics 112: 441-457.
4. Barnes RL, McCulloch R, (2007) Trypanosoma brucei homologous recombination is dependent on substrate length and homology, though displays a differential dependence on mismatch repair as substrate length decreases. Nucleic Acids Res 35: 3478-3493.
5. Shao C, Stambrook PJ, Tischfield JA, (2001) Mitotic recombination is suppressed by chromosomal divergence in hybrids of distantly related mouse strains. Nat Genet 28: 169-172.
6. Blackburn AC, McLary SC, Naeem R, Luszcz J, Stockton DW, et al. (2004) Loss of heterozygosity occurs via mitotic recombination in Trp53+/- mice and associates with mammary tumor susceptibility of the BALB/c strain. Cancer Res 64: 5140-5147.
7. Barber LJ, Youds JL, Ward JD, McIlwraith MJ, O'Neil NJ, et al. (2008) RTEL1 maintains genomic stability by suppressing homologous recombination. Cell 135: 261-271.
8. Moynahan ME, Jasin M, (2010) Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol 11: 196-207.
9. Bacolod MD, Schemmann GS, Wang S, Shattock R, Giardina SF, et al. (2008) The signatures of autozygosity among patients with colorectal cancer. Cancer Res 68: 2610-2621.
10. Bacolod MD, Schemmann GS, Giardina SF, Paty P, Notterman DA, et al. (2009) Emerging paradigms in cancer genetics: some important findings from high-density single nucleotide polymorphism array studies. Cancer Res 69: 723-727.
11. Assie G, LaFramboise T, Platzer P, Eng C, (2008) Frequency of germline genomic homozygosity associated with cancer cases. JAMA 299: 1437-1445.
12. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, et al. (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 101: 2999-3004.
13. Shoemaker RH, (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6: 813-823.
14. Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, et al. (2007) Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 6: 820-832.
15. Ku CS, Naidoo N, Teo SM, Pawitan Y, (2011) Regions of homozygosity and their impact on complex diseases and traits. Hum Genet 129: 1-15.
16. Beroukhim R, Lin M, Park Y, Hao K, Zhao X, et al. (2006) Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol 2: e41.
17. Cheng Li, Wing W, (2006) DNA-Chip Analyzer (dChip). In: Parmigiani Giovanni, Garrett Elizabeth, Irizarry Rafael, Zeger Scott, editors. The Analysis of Gene Expression Data Methods and Software Springer London pp. 120-141.
18. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575.
19. Wang K, Li M, Hadley D, Liu R, Glessner J, et al. (2007) PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res 17: 1665-1674.
20. Griffiths-Jones S, Saini HK, van DS, Enright AJ, (2008) miRBase: tools for microRNA genomics. Nucleic Acids Res 36: D154-D158.
21. Ried K, Finnis M, Hobson L, Mangelsdorf M, Dayan S, et al. (2000) Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum Mol Genet 9: 1651-1663.
22. Finnis M, Dayan S, Hobson L, Chenevix-Trench G, Friend K, et al. (2005) Common chromosomal fragile site FRA16D mutation in cancer cells. Hum Mol Genet 14: 1341-1349.
23. Huang H, Reed CP, Mordi A, Lomberk G, Wang L, et al. (1999) Frequent deletions within FRA7G at 7q31.2 in invasive epithelial ovarian cancer. Genes Chromosomes Cancer 24: 48-55.
24. Velickovic M, Delahunt B, Grebe SK, (1999) Loss of heterozygosity at 3p14.2 in clear cell renal cell carcinoma is an early event and is highly localized to the FHIT gene locus. Cancer Res 59: 1323-1326.
25. Denison SR, Callahan G, Becker NA, Phillips LA, Smith DI, (2003) Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer. Genes Chromosomes Cancer 38: 40-52.
26. Lorenzi PL, Reinhold WC, Varma S, Hutchinson AA, Pommier Y, et al. (2009) DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther 8: 713-724.
27. Narva E, Autio R, Rahkonen N, Kong L, Harrison N, et al. (2010) High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity. Nat Biotechnol 28: 371-377.
28. Carr LL, Gottschling DE, (2008) Does age influence loss of heterozygosity? Exp Gerontol 43: 123-29.
29. Moragoda L, Jaszewski R, Kulkarni P, Majumdar AP, (2002) Age-associated loss of heterozygosity of tumor suppressor genes in the gastric mucosa of humans. Am J Physiol Gastrointest Liver Physiol 282: G932-G936.
30. Arlt MF, Miller DE, Beer DG, Glover TW, (2002) Molecular characterization of FRAXB and comparative common fragile site instability in cancer cells. Genes Chromosomes Cancer 33: 82-92.
31. Limongi MZ, Pelliccia F, Rocchi A, (2003) Characterization of the human common fragile site FRA2G. Genomics 81: 93-97.
32. Zlotorynski E, Rahat A, Skaug J, Ben-Porat N, Ozeri E, et al. (2003) Molecular basis for expression of common and rare fragile sites. Mol Cell Biol 23: 7143-7151.
33. Condeelis J, Singer RH, Segall JE, (2005) The great escape: when cancer cells hijack the genes for chemotaxis and motility. Annu Rev Cell Dev Biol 21: 695-718.
34. Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, et al. (2004) A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 64: 7022-7029.
35. Wyckoff JB, Jones JG, Condeelis JS, Segall JE, (2000) A critical step in metastasis: in vivo analysis of intravasation at the primary tumor. Cancer Res 60: 2504-2511.
36. Kitamura T, Fujishita T, Loetscher P, Revesz L, Hashida H, et al. (2010) Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model. Proc Natl Acad Sci U S A 107: 13063-68.
37. Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, et al. (2007) CCR2 expression correlates with prostate cancer progression. J Cell Biochem 101: 676-685.
38. Johrer K, Zelle-Rieser C, Perathoner A, Moser P, Hager M, et al. (2005) Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma. Clin Cancer Res 11: 2459-2465.
39. Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Morris SB, et al. (1998) Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J Clin Invest 102: 465-472.
40. Dorsam RT, Gutkind JS, (2007) G-protein-coupled receptors and cancer. Nat Rev Cancer 7: 79-94.
41. Yan W, Chen X, (2009) Identification of GRO1 as a critical determinant for mutant p53 gain of function. J Biol Chem 284: 12178-12187.
42. Doll D, Keller L, Maak M, Boulesteix AL, Siewert JR, et al. (2010) Differential expression of the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and their impact on metastatic disease and survival. Int J Colorectal Dis 25: 573-581.
43. Sato E, Fujimoto J, Toyoki H, Sakaguchi H, Alam SM, et al. (2007) Expression of IP-10 related to angiogenesis in uterine cervical cancers. Br J Cancer 96: 1735-1739.
44. Yuan A, Chen JJ, Yao PL, Yang PC, (2005) The role of interleukin-8 in cancer cells and microenvironment interaction. Front Biosci 10: 853-865.
45. He M, Qin J, Zhai R, Wei X, Wang Q, et al. (2008) Detection and identification of NAP-2 as a biomarker in hepatitis B-related hepatocellular carcinoma by proteomic approach. Proteome Sci 6: 10.
46. Cervi D, Yip TT, Bhattacharya N, Podust VN, Peterson J, et al. (2008) Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 111: 1201-1207.